Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao et al

Ann Rheum Dis. 2021 May;80(5):e64. doi: 10.1136/annrheumdis-2020-218196. Epub 2020 Jun 16.

¹ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA zswallace@partners.org.

No abstract available

Keywords: autoimmunity; biological therapy; epidemiology.

Publication types